Navigation Links
Independent Data Safety Monitoring Board Recommends Continuation of Sangart's Pivotal Phase III Trials of Hemospan(R)
Date:12/13/2007

SAN DIEGO, Dec. 13 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen transport agents, today announced that an independent data safety monitoring board (DSMB) has recommended the continuation of both Phase III clinical trials of Sangart's lead blood substitute product, Hemospan(R), under current protocols.

This recommendation follows the DSMB's review of the blinded data from the first one-third of the 830 patients to be enrolled in two ongoing Phase III pivotal studies in Europe. The DSMB will conduct another review after two- thirds of the patients have been enrolled.

"We are pleased to have the DSMB's approval and look forward to advancing these important Phase III studies," commented Dr. Robert Winslow, Chairman, President and CEO of Sangart.

Hemospan is a hemoglobin-based oxygen transport agent designed to serve as an oxygen therapeutic and as an alternative to blood transfusions. A key property of Hemospan is its high oxygen affinity which results in targeted oxygen delivery to tissues at risk of oxygen deprivation.

About Sangart

Sangart is a privately held biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as oxygen transport agents.

Dr. Robert Winslow, a world-renowned authority in the field of oxygen transport, founded Sangart in 1998. In the two decades prior to founding Sangart, Dr. Winslow and his colleagues studied and defined mechanisms of oxygen transport by cell-free hemoglobin solutions, funded by competitive grants from the National Institutes of Health and the Department of Defense. The counterintuitive discoveries by Dr. Winslow's group on the effective action of oxygen transport agents have been patented and published in numerous scientific articles. From this experience, Sangart's lead product, Hemospan, was designed using unique polyethylene glycol conjugation to create a hemoglobin-based product that is intended to serve as an oxygen therapeutic and as an alternative to donated blood.

The key breakthroughs in the development of Hemospan were the understanding of the mechanisms of vasoconstriction caused by cell-free hemoglobin and the development of simplified production methods that are designed to make the final product commercially viable.

Sangart's is headquartered in San Diego, California. To learn more about Sangart, please visit the company's website at http://www.sangart.com.

Media Contact:

Meghan Feeks

Richard Lewis Communications, Inc.

212-827-0020

mfeeks@rlcinc.com


'/>"/>
SOURCE Sangart, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom
5. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
6. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
7. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
8. Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care
9. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
10. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
11. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... (PRWEB) , ... June 19, 2017 , ... A colony ... among its cells and tissues by delivering pollen and nectar containing nutrients necessary for ... means to stay healthy. , Many recent indicators point to a decline in honey ...
(Date:6/15/2017)... ... June 15, 2017 , ... Cybrexa Therapeutics, a start-up cancer ... financing in the amount of $6 million. An investment vehicle affiliated with HighCape ... , The Series B funding will enable Cybrexa to complete the build-out of ...
(Date:6/14/2017)... ... 2017 , ... Slone Partners welcomed a panel of premier ... search firm, “Building Value in Precision Medicine: Can We Overcome the Obstacles?” , ... an open discussion with expert panelists Troy Cox, CEO of Foundation Medicine, Barbara ...
(Date:6/14/2017)... ... June 14, 2017 , ... The newest company to ... therapeutic antibodies using rabbits that express human genes. ATGC, a spin out of the ... in 2015, ATGC is a translational genomics company. Its founders are among the ...
Breaking Biology Technology:
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:3/30/2017)... March 30, 2017 The research team of ... three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae ... realm of speed and accuracy for use in identification, crime investigation, ... cost. ... A research ...
Breaking Biology News(10 mins):